Investment
Features
FeesSafety
Academy
More
Pluang+

Primary Health Properties shows strong growth and a 7.5% dividend yield, boosted by Assura merger savings.

Company Fundamentals
30 Jul 2026
Proactive Investors
View Source
Bullish
pluang ai news

Primary Health Properties Plc continues to demonstrate solid organic rental growth and a robust 7.5% dividend yield, supported by accelerating rents and cost savings from its merger with Assura. The company reported a 9% rise in interim earnings per share and a 2.8% increase in its interim dividend. Cost savings have significantly reduced operating expenses, and efforts are underway to lower debt and financing costs. The firm is also planning a joint venture for its private hospital portfolio, maintaining a 50% stake and management role, positioning it well for future growth and stable returns.

More News

AXT, Inc. expects nearly 90% revenue growth driven by AI demand and $100M indium phosphide backlog.

AXT, Inc. expects nearly 90% revenue growth driven by AI demand and $100M indium phosphide backlog.

AXT, Inc. has secured a long-term supply deal with Lumentum Holdings, reinforcing its role in providing indium phosphide wafers for advanced tech products. The company projects a nearly 90% revenue increase, fueled by strong demand from the AI sector...

Company Fundamentals
Bullish
47 minutes ago
Sanofi releases its half-year 2026 financial report and updates on business growth and pipeline progress.

Sanofi releases its half-year 2026 financial report and updates on business growth and pipeline progress.

Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double...

Company Fundamentals
Bullish
1 hour ago
Sanofi releases its half-year 2026 financial report and updates on business progress.

Sanofi releases its half-year 2026 financial report and updates on business progress.

Sanofi has published its financial report for the first half of 2026, available on its website and filed with the French financial authority (AMF). The biopharmaceutical company highlights its innovation in R&D and use of AI to drive long-term growth...

Company Fundamentals
Neutral
1 hour ago
Humana's stock target raised to $390 amid mixed analyst views and steady 2026 outlook

Humana's stock target raised to $390 amid mixed analyst views and steady 2026 outlook

Robert W. Baird raised Humana's stock price target to $390 from $205, signaling potential upside despite a 5.87% stock drop on a turbulent market day. Meanwhile, Raymond James downgraded Humana to Market Perform, indicating expected performance in li...

Company Fundamentals
Neutral
1 hour ago
Evercore ISI raises Teradyne price target to $420 on strong AI-driven revenue growth.

Evercore ISI raises Teradyne price target to $420 on strong AI-driven revenue growth.

Evercore ISI has increased its price target for Teradyne to $420 from $370, maintaining an Outperform rating due to the company's robust AI-driven growth. Teradyne reported record Q2 revenues of $1.33 billion, a 103.9% increase year-over-year, and no...

Analyst Insights
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App